Mark Carnegie-Brown

Always interesting to watch closely when Novo Holdings is making a move. ADCs are designed to deliver a potent chemotherapy drug directly to cancer cells by attaching it to an antibody that recognizes a specific protein in the cancer cells. This allows for more targeted treatment, potentially reducing side effects compared to traditional chemotherapy. The novel class of ADCs being developed by Myricx Bio, could potentially provide even more targeted and effective treatments. That's value. When treating cancer, it's all hands on deck. Bravo Novo Holdings and Myricx Bio! #biotech #lifesciences #health #innovation #antibodies #oncology

14

Such an exciting clinical milestone for Tryptamine Therapeutics (Tryp Therapeutics) with the company releasing clinically significant data from its second Phase 2a clinical trial utilising TRP-8802 (oral-psilocybin), this time, in Fibromyalgia Syndrome. For the pharmaceutical industry, from "New Chemical Entity" (NCE) status to completion of Phase 2a studies can take anywhere between 6 - 10 years and cost between US$200M - US$1B. Since Tryp Therapeutics had spent the last 4 years building data and IP around TRP-8802/8803 as well as selecting novel indications of high unmet clinical need, the company entered the ASX with a significant head start on potential competitors and will hold three levels of IP protection - molecule, IV-infusion delivery and novel indications. Please follow us at Tryp Therapeutics or invest in us [ASX : TYP]. #Fibromyalgia #FMS #Tryptamine #Tryp #neuroplasticity #psychedelic #psilocybin #psilocin #infusion

21

3 Comments

🌟 Congratulations to our portfolio company Verinnogen on its Innovate UK grant! The grant will support its collaboration with the National Physical Laboratory (NPL) to optimise its 3D surface profiling technology, designed to measure grafted tumours in preclinical cancer models more accurately, precisely, and quickly than traditional methods. Find out more below ⬇ #OnMyHorizon #Oncology Cancer Research Horizons

11

How do growth factors produce cell division? Growth factors promote cell proliferation by initiating a chain of events when they bind to their receptors, which ripple through the cell. Our latest blog article explains these events. https://lnkd.in/eSS-qsjS

17

We, the team at CellCentric, are pioneering a new approach to treat multiple myeloma, with an oral p300/CBP inhibitor drug, inobrodib. Huge progress has been made in treating the disease, particularly with recent antibody-based therapies (BCMA targeting agents, TCEs). But 75% of people diagnosed still die of the condition. Beyond and alongside existing approaches, there is a need for oral agents with novel modes of action. Community based delivery also helps address health inequities, meeting the needs of people who are not suitable or able to access more complex treatments in specialist centres. New financing maintains full momentum to registration studies. RA Capital Management and Pfizer Ventures now join Morningside as shareholders. Further additional contribution too from the American Cancer Society’s impact fund, BrightEdge. Total funding: $60.7m. Great to have Laura Stoppel of RA Capital joining the Board, as well as Irena Melnikova from Pfizer Ventures. Press release: https://lnkd.in/d9QpfvFz Endpoints coverage: https://lnkd.in/dg4geESK. Many thanks Lei Lei Wu Business Weekly: https://lnkd.in/e4ZsaJkA Many thanks Tony Quested #multiplemyeloma Debbie Haynes Tomasz Knurowski Karen Clegg Kris Frese Thea Stanway

59

1 Comment

https://lnkd.in/gX2XPFDM Monkeypox Virus - Update From 2BScientific Ltd. A recent outbreak of Monkeypox has sparked growing global discussion, with particular concern in the UK, where over 40 cases were confirmed in July 2024. This resurgence is drawing comparisons to the SARS-CoV-19 pandemic due to the similar measures required for isolation and the uncertainties surrounding the virus. The lack of comprehensive knowledge about Monkeypox a cause for concern, as despite being identified decades ago, there are still critical gaps in our understanding. Monkeypox, a zoonotic disease, typically spreads from animals to humans. However, this outbreak has outlined the virus's ability to transmit from human to human through direct contact with lesions, body fluids, respiratory droplets, and contaminated materials. This mode of transmission poses a significant challenge in today’s densely populated and highly connected urban environments, where infectious diseases can spread rapidly. The current outbreak highlights the need for vigilant public health responses and highlights the importance of global cooperation to help contain this virus. 2BScientific Ltd. offers a range of products that can benefit investigations and studies with regards to monkeypox. This includes monkeypox ELISA kits, Anti-Monkeypox virus (to be used with ELISA and immunofluorescence), as well as a wide selection of ELISA, PCR, and immunofluorescence products. #monkeypox #2bscientific #hereforyou

16

Are you a manufacturer of Digital Therapeutics (DTx) with a focus on the UK market? In this blog post, we delve into the intricacies of Digital Therapeutics (DTx) regulation in the UK, especially in light of Brexit in January 2020. 👉 https://lnkd.in/eqYb38ZF #DTx #DigitalTherapeutics #RegulatoryAffairs #Brexit

11

https://lnkd.in/eMnPdwZs Read the latest blog on the comparison of molecular detection Techniques: SYBR Green Vs. TaqMan written by our expert Product Manager John Probert at 2BScientific Ltd. #TaqMan and #SYBR Green #PCR techniques are critical for research in molecular biology, driving advancements in investigations and diagnostics. Here’s why they're essential: Gene Expression Analysis and Biomarker Detection: SYBR Green PCR for screening, followed by TaqMan PCR for precise quantification and validation. Microbial Detection and Oncology: SYBR Green PCR for broad screening, TaqMan PCR for accurate quantification of specific targets. Epigenetics Studies, Pharmacogenomics, and Personalised Medicine: SYBR Green PCR's early assessment complements TaqMan PCR's precision, aiding informed treatment decisions. Check out the detailed article from 2BScientific covering the utilisation of TaqMan and SYBR Green, along with our selection of superior research reagents suitable for PCR and various research applications. #hereforyou #2bscientific #molecular

7

Here's our fifth SMi Short. This time we move away from discussing the science behind our technology and introduce some of the broader process approaches we take. In this short we discuss our approach to risk management, a subject which is very close to my heart, and how we've brought together two international standards to enable the same risk management process to be used for both diagnostic and research-use-only products. https://lnkd.in/eYMK78QP

5

2 Comments

There is an absolute, pressing need to reduce the prices of advanced therapies, especially gene therapies If you believe the cost-benefit analyses out there (which I pretty much do), current prices can make sense - but only in the long term. For example, keeping to round numbers, lifetime Hemophilia A healthcare costs are ~$20 million, life expectancy of those afflicted is ~70 years, so Roctavian at ~$2 million (probable price w/discounts etc.) only has to work for ~7 years to break even. It probably will work for at least that long and also provides material QOL benefits which often come with further health cost savings, like markedly reduced ER visits for bleeding events But also significant is the short-term impact of these prices on payers: having to write such multi-million dollar checks is a cash-flow problem more than a cash problem, but a problem nonetheless. As Bloomberg News’s excellent Gerry Smith writes below, the immediate economic impact of such claims (‘lightning strikes’ as he terms them) on smaller insurers is real. It’s societally disturbing, but hard to blame them for trying to avoid these lightning strikes by excluding such therapies in the fine print However, it’s equally unfair just to expect biopharma to reduce prices, as even at current levels this would land most far from break-even on development and manufacturing costs. The industry needs to show decent margins to justify further investment in advanced therapies. But if we can’t afford even ultra/rare treatments, forget about advanced therapies for more common conditions As I see it there are only a few options: * Reduce COGS (a partial solution) * Amortization and/or performance-based installment pricing. I think these could be offered by biopharma or even governmentally forced upon them, perhaps in return for longer exclusivity * I’m open to suggestions (read the article first though!)…

59

7 Comments

This is such an important subject and a big thanks to British In Vitro Diagnostics Association (BIVDA) for raising it at a Parliamentary Reception this week. Getting innovations into the NHS is challenging, especially for SMEs who have limited resources and significant pressures from their investors to get sales. One of the unfortunate consequences of this is that SMEs are forced to focus their efforts on larger international markets with quicker pathways to adoption, and UK patients cannot access homegrown innovations. Surely there must be a way to reduce the barriers to adoption to ensure British innovations are available in their home market first? #skincancer #melanoma #diagnostic # innovation #AMBLor

24

1 Comment

The market for bispecific antibodies is growing, creating opportunities for pharma and biotech companies. However, an understanding of bsAbs is required before organisations can start their journey. In this blog post, our own Desmond Schofield explores what bsAbs are, their history, and future prospects for the sector. If you're ready to start exploring the therapeutic potential of these antibodies, the later sections detail how evitria can support you or you can simply get in touch with our team today. #Antibodies #BispecificAntibodies #Biotech #Biopharma

18

1 Comment

Antibody purification is an essential step in producing high-quality antibodies, but there's no one 'right' approach. At evitria, we offer a range of purification services designed to meet the diverse needs of our clients' projects. This includes offering alternative resins to aid protein capture for antibodies without a strong affinity to Protein A. Find out what these are and the methods we use for protein polishing in our blog. If you have any questions, please message me or the rest of the team. With evitria, your project is in safe hands. #AntibodyManufacturing #Antibodies #AntibodyPurification #ProteinCapture

14

Want to catch bacterial contamination early in your CHO cell cultures? Aber Instruments Ltd's webinar (link below!) explores how conductivity & dielectric spectroscopy can help with real-time monitoring & process automation. https://lnkd.in/eQPxdiGj #WebinarAlert #bioprocess #biotechnology #ProcessAutomation #CellCulture #ContaminationDetection #learning

4

Phacilitate's Advanced Therapies Europe is now just over a week away, and I'm going to be highlighting some stand-out Technical sessions for the #ATE24 meeting agenda (This may have to be a two-parter!!) ⚙ Building Essential Manufacturing Competencies for ATMPs from the Outset 🌟 Chaired by Jean-Pierre Cabaniols, Cellectis 🌟 Presentations from: Jenny Stjernberg, ScaleReady, Sofia Håkansson Buch, Novo Nordisk & Aled Charles, Rentschler Biopharma ⚙ Revolutionizing Cell Therapy: MSAT Innovations, Insights, and Strategic Decisions for Developers 🌟 Chaired by Niloofar Davoodi, Takeda 🌟 Presentations from: Volker Huppert, Glycostem Therapeutics, Emilie Gauthy, Zelluna Immunotherapy & Emilie Kleiren, Legend Biotech ⚙Scaling Up: Manufacturing Strategies for Commercial Success in Cell and Gene Therapy 🌟 Chaired by Alessandro Linciano, Novartis 🌟 Presentations from: Nuno Madeira do Ó, OkuloVision, Inc, Olga de la Rosa Morales, Takeda, Jean-Pierre Cabaniols, Cellectis & Michelle Janas, MasterControl ⚙ Flexibility in Action: Harnessing Adaptive Vector Platforms for Gene Therapy Manufacturing 🌟 Chaired by Samarendra Mohanty, Nanoscope Therapeutics Inc. 🌟 Presentations from: Simon Briggs, Orchard Therapeutics - U.S., Cedrick R., SK pharmteco, Su Xiao, Neurophth Therapeutics / 纽福斯生物科技有限公司 🌟 A fireside chat between: John W. Hadden II, ViroCell Biologics & Chris Williams, Autolus Therapeutics ...Definitely going to need a part two! I'll be including further sessions in a thematic post about the agenda, but these are some stand-out sessions for Regulatory and technical excellence in cell and gene therapies, with case studies, expert fireside chats and collaborative panels by global and European ATMP leaders! Need a pass? Reach out!! #AdvancedTherapiesEurope #ATE24 #genetherapy #celltherapy #cellandgenetherapy #ATMPs #AdvancedTherapies #geneticmedicine #biotech #biotherapeutics

47

2 Comments

💡 Our wonderful Oncology Therapeutic Experts at ICON Biotech collaborated with Citeline and industry specialist to uncover how new wave technology-driven therapeutics are reshaping oncology development! Have a read through the insightful discussion and feel free to reach out if you would like to connect with Andreas Dreps and Muaiad Kittaneh for a chat! #oncologydevelopment #emergingtechnologies #clinicalresearch

2

**Challenging Times for Pharma CROs** Since January, the preclinical contract research sector has faced significant challenges, with companies like Evotec, Wuxi Apptec, and Gingko Bioworks experiencing a sharp decline in their stock prices, ranging from 60% to 80%. Amidst this downturn, Charles River has managed to maintain stability. It is noteworthy that despite the well-publicized challenges faced by Wuxi Apptec, it has outperformed both Evotec and Gingko Bioworks, which are grappling with their own set of issues. This dramatic decrease in share prices appears to be linked to the broader contraction in big pharma headcount and layoffs. Reduced orders have led to diminished revenue and a slowdown in research activities, raising concerns about a potential vicious cycle for the contract research lab industry.

13

2 Comments

*The Big Interview: Mission Genomics to launch the UK economy* I’m incredibly proud to share this insightful and thought-provoking article in the latest issue of Bioscience Today, written by our Chief Scientific Officer Dr Stuart J Grice. In this piece, Stuart shares his thoughts on how public investment in genetic testing can not only save lives but also foster cross-sector investment and innovation in preventative health. The UK life sciences sector continues to produce fantastic innovation, but we are still behind the curve in the adoption and translation of these advancements into the public domain. Public-private partnerships are likely to play a crucial role in driving disease prevention initiatives and realising the benefits of new discoveries. Stuart's keen insight and intelligent analysis are an asset to FitnessGenes, and I look forward to seeing more authored pieces from him in the coming months. You can read the article for yourself here (~3-minute read): https://lnkd.in/e4A8jweW #BigInterview #MissionGenomics #GeneticTesting #PublicInvestment #PreventativeHealth #LifeSciences #Innovation #Healthcare #PublicPrivatePartnerships #DiseasePrevention #HealthTech #FitnessGenes #ScientificInsights #ThoughtLeadership #UKHealth #BioScienceToday #FutureOfHealth #Genomics #HealthInnovation #MedicalResearch #DNA

23

1 Comment